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Abstract
Introduction: Progressive fibrosis in systemic sclerosis (SSc) is linked to aberrant transforming growth factor beta
(TGF-beta) signaling. Peroxisome proliferator-activated receptor gamma (PPAR-gamma) blocks fibrogenic TGF-beta
responses in vitro and in vivo. Reduced expression and function of PPAR-gamma in patients with SSc may
contribute to progression of fibrosis. Here we evaluated the levels of adiponectin, a sensitive and specific index of
PPAR-gamma activity, as a potential fibrogenic biomarker in SSc.
Methods: Adiponectin levels were determined in the sera of 129 patients with SSc and 86 healthy controls, and
serial determinations were performed in 27 patients. Levels of adiponectin mRNA in skin biopsies from SSc patients
were assessed in an expression profiling microarray dataset. Regulation of adiponectin gene expression in
explanted human subcutaneous preadipocytes and fibroblasts was examined by real-time quantitative PCR.
Results: Patients with diffuse cutaneous SSc had reduced serum adiponectin levels. A significant inverse correlation
between adiponectin levels and the modified Rodnan skin score was observed. In longitudinal studies changes in
serum adiponectin levels were inversely correlated with changes in skin fibrosis. Skin biopsies from a subset of SSc
patients showed reduced adiponectin mRNA expression which was inversely correlated with the skin score. An
agonist ligand of PPAR-gamma potently induced adiponectin expression in explanted mesenchymal cells in vitro.
Conclusions: Levels of adiponectin, reflecting PPAR-gamma activity, are correlated with skin fibrosis and might
have potential utility as a biomarker in SSc.
Introduction
Systemic sclerosis (SSc) is a multisystem disorder with
protean clinical manifestations and substantial patient-
to-patient heterogeneity [1]. Skin fibrosis characteristi-
cally shows rapid progression during early-stage disease
but then reaches a plateau phase followed by slow
regression. Transforming growth factor-beta (TGF-b)
plays a key role in initiating and sustaining fibroblast
activation and myofibroblast differentiation in SSc [2].
Microarray-based expression profiling of SSc skin biop-
sies shows an association that a ‘TGF-b-activated gene
signature’ is associated with extensive skin involvement
[3]. Multiple physiologic mechanisms regulate TGF-b
signaling to prevent excessive tissue remodeling and
fibrosis. One important endogenous anti-fibrotic defense
mechanism involves the peroxisome proliferator-acti-
vated receptor-gamma (PPAR-g) pathway, which blocks
TGF-b responses [4].
The nuclear receptor PPAR-g, initially identified in
adipose tissue, plays key roles in regulation of adipogen-
esis, insulin sensitivity, and energy homeostasis [5]. In
addition to being expressed in adipocytes, PPAR-g is
expressed in endothelial cells, vascular smooth muscle
cells, macrophages, and fibroblasts [4,6]. Endogenous
and diet-derived fatty acids and eicosanoids such as
prostaglandin J2 (PGJ2) act as low-affinity natural PPAR-
g ligands, whereas the thiazolidenedione drugs are
potent synthetic PPAR-g agonists [7]. Recent studies
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identified an entirely novel function for PPAR-g in regu-
lation of matrix homeostasis [8]. Exposure of fibroblasts
to pharmacological PPAR-g ligands resulted in suppres-
sion of collagen synthesis, myofibroblast differentiation,
and other TGF-b-induced fibrotic responses in vitro
[4,9,10]. Moreover, treatment of mice with PPAR-g ago-
nists prevented and attenuated bleomycin-induced scler-
oderma in vivo [11]. The significance of the anti-fibrotic
activity of PPAR-g is highlighted by genetic targeting
experiments that demonstrate constitutive collagen
overexpression and excessive fibrogenesis in PPAR-g-
null fibroblasts in vitro and in vivo [12]. Importantly,
PPAR-g expression and activity are reduced in SSc skin
biopsies and explanted fibroblasts and are inversely cor-
related with fibrogenic markers in the lesional skin
[13,14]. These observations suggest that impaired PPAR-
g expression or function underlies unopposed fibroblast
activation and progression of fibrosis in SSc. Assessing
PPAR-g expression or activity therefore might be a
novel approach for assessing fibrogenic activity in SSc.
Adiponectin is a 244-amino acid hormone secreted
from white adipose tissue that regulates insulin sensitiv-
ity and energy balance. The adiponectin gene is located
on chromosome 3q27, a susceptibility locus for diabetes
and metabolic disorders. Adiponectin transcription is
tightly regulated by PPAR-g through direct binding to
conserved cis-acting regulatory DNA elements. Circulat-
ing adiponectin is decreased in obesity and the meta-
bolic syndrome, and levels are increased in mice and in
humans after treatment with PPAR-g agonist agents
[15]. Since serum adiponectin levels faithfully mirror
PPAR-g activity, adiponectin is now increasingly used as
a biomarker of efficacy for PPAR-g therapy [15]. In view
of the PPAR-g defect seen in SSc, we hypothesized that
circulating adiponectin might be reduced in some
patients with SSc. We therefore determined adiponectin
levels in 129 patients with well-characterized SSc and
correlated levels with clinical and laboratory features of
disease. The results reveal significantly reduced adipo-
nectin levels in diffuse cutaneous SSc (dcSSc) patients
with early-stage disease, inverse correlation with the
extent of skin fibrosis, and rising levels that parallel
improved skin scores over time.
Materials and methods
Patients
Written informed consents, approved by the institu-
tional review board of Northwestern University were
acquired and serum samples were obtained from 129
patients with SSc - 50 with dcSSc and 79 with limited
cutaneous SSc (lcSSc) - evaluated at the Northwestern
Scleroderma Program between February 2009 and April
2010. In an additional cohort of 27 patients with dcSSc,
two serum samples separated by more than 10 months
were obtained and analyzed. Clinical and laboratory
information obtained at the time of serum sampling
included age, gender, ethnicity, smoking history, body
mass index (BMI), disease duration (interval between
first SSc-related non-Raynaud event and blood sam-
pling), modified Rodnan skin score (MRSS) (0 to 51),
forced vital capacity (FVC), and carbon monoxide diffu-
sion capacity (DlCO) as a percentage of predicted high-
resolution computerized tomography of the chest (Table
1 and Additional file 1). Screening for pulmonary hyper-
tension (PH) was performed by Echo/Doppler or by
right heart catheterization and provisionally defined as
estimated pulmonary artery systolic pressure of at least
40 mm Hg or mean pulmonary artery pressure of at
least 25 mm Hg, respectively. Anti-nuclear autoantibo-
dies were detected by indirect immunofluorescence, and
antibodies against topoisomerase-1, centromere, and
RNA polymerase III were assayed. Control serum sam-
ples were collected from 86 healthy volunteers (Table 1).
Determination of serum adiponectin levels
Serum samples were frozen at -80°C until assayed. Adi-
ponectin levels were measured by using a multiplex
assay kit (EMD Millipore, Billerica, MA, USA) in accor-
dance with the instructions of the manufacturer. Briefly,
serum samples (1:100 dilution) and standards were
added to the wells, along with sonicated beads. After
incubation and washing of the wells, antibodies were
added, followed by streptavidin-phycoerythrin. Wells
were then washed, and measurements on a Luminex
100 platform (Luminex Corporation, Austin, TX, USA)
were performed. The assay detects all three (low-, med-
ium-, and high-molecular weight) forms of adiponectin.
Regulation of adiponectin gene expression
Human subcutaneous preadipocytes (Zen-Bio, Inc.,
Research Triangle Park, NC, USA) and neonatal foreskin
fibroblasts were maintained at 37°C in an atmosphere of
5% CO2 in preadipocyte medium (PM) (Zen-Bio, Inc.)
or Dulbecco’s modified Eagle’s medium supplemented
with 10% fetal bovine serum, 1% vitamins, 1% penicillin/
streptomycin, and 2 mM L-glutamine (all from Bio-
Whittaker, Walkersville, MD, USA). Cells were studied
between passages 4 and 8 at early confluence. Cultures
were incubated in the presence or absence of pioglita-
zone (10 μM). After 48 hours of incubation, cultures
were harvested, and mRNA levels were examined by
real-time quantitative polymerase chain reaction (qPCR)
by using primers for adiponectin (forward, 5’-TATCCC-
CAACATGCCCATTCG-3’; reverse, 5’-TAGGCAAAG-
TAGTACAGCCCA-3’) and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) (forward, 5’-CATGAGAAG-
TATGACAACAGCCT-3’; reverse, 5’-AGTCCTTCCAC-
GATACCAAAGT-3’).
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Adiponectin gene expression in skin biopsies
The generation and analysis of the genome-wide expres-
sion microarray dataset using skin biopsies from patients
with SSc and healthy controls have been described
(Gene Expression Omnibus accession number GSE9285)
[16]. The expression levels of adiponectin mRNA in
each skin biopsy were extracted from this dataset and
centered on its mean value across all arrays.
Statistical analysis
Mann-Whitney U tests or Kruskal-Wallis tests were
used to compare adiponectin levels. The correlation
between adiponectin levels and various values were ana-
lyzed by Spearman rank correlation test. Owing to non-
normal distribution of the data, summary statistics are
expressed as medians and interquartile ranges (IQRs).
Data were analyzed by using SPSS Statistics 19 (SPSS
Inc., Chicago, IL, USA). A P value of less than 0.05 was
considered statistically significant.
Results and Discussion
As expected, serum adiponectin levels in both control
subjects and SSc patients were positively correlated with
age and negatively correlated with BMI. Moreover, adipo-
nectin levels were significantly lower in males than
females, as reported previously [17]. The median levels of
adiponectin were 14.7 μg/mL (IQR 15.4) among patients
with SSc and 15.3 μg/mL (IQR 11.2) in healthy controls
(P = 0.49). While there were no significant differences in
adiponectin levels between patients and controls when
adjusted for differences in age, gender, and ethnicity,
patients with dcSSc (n = 50) had significantly lower adi-
ponectin levels (median 10.0 μg/mL, IQR 11.3) than
those with lcSSc (n = 79, median 18.3 μg/mL, IQR 13.1,
P < 0.001) (Figure 1a). Further analyses revealed signifi-
cant differences in adiponectin levels between SSc
patients with or without anti-centromere antibody: med-
ian 21.5 μg/mL (IQR 20.3) versus 13.3 μg/mL (IQR 14.8)
(P = 0.015), respectively. When grouped according to dis-
ease duration, patients with disease in a relatively early
stage (arbitrarily defined as fewer than 18 months from
the first non-Raynaud manifestation, n = 25) had low adi-
ponectin levels (median 9.6 μg/mL, IQR 8.5) in compari-
son with patients with disease in the late stage (defined
as more than 36 months, n = 91) (median 17.1 μg/mL,
IQR 15.3, P = 0.004) (Figure 1c). The lower levels of adi-
ponectin in the early stage of disease, when progression
of skin fibrosis is thought to be the most active, might
reflect reduced tissue PPAR-g activity. The differences in
adiponectin levels were significant even when adjusted
for age, gender, ethnicity, and BMI (P < 0.001).
The difference in adiponectin levels between patients
with lcSSc and those with dcSSc suggested that adipo-
nectin, as a marker of PPAR-g signaling in the skin,
might be correlated with skin fibrosis. Indeed, we
demonstrated a weak but statistically significant inverse
correlation between adiponectin levels and the extent of
skin fibrosis (r = -0.261, n = 124, P = 0.003) (Figure 1b).
This correlation persisted even when corrected for age,
gender, ethnicity, and BMI. A more robust correlation
between MRSS and adiponectin levels was seen in Scl-
70-positive patients, suggesting the association of
reduced PPAR-g activity with active skin disease (Figure
1b). In contrast to the skin score, neither FVC nor
DlCO or radiologic evidence of pulmonary fibrosis
could be demonstrated to have a significant correlation
with serum adiponectin levels (Additional files 1 and 2).
The correlation of serum adiponectin levels with skin
but not lung fibrosis points to potential differences in
the pathomechanisms underlying fibrosis in these
organs, and PPAR-g has a more prominent role in skin
fibrosis than in lung fibrosis.









Age in years, median (range) 43 (19-64) 53 (21-82) 51 (21-65) 55 (21-82)
Females, percentage 30 85 78 88
Ethnicity
Caucasian 100% 71% 68% 75%
African-American 14% 14% 13%
Other 15% 18% 12%
Disease duration N/A
0-18 months 19% 36% 9%
19-36 months 10% 12% 9%
> 36 months 71% 52% 82%
MRSS from 0 to 51, median (range) N/A 6 (2-45) 16 (2-45) 4 (2-25)
BMI in kg/m2, median (range) N/A 25 (14-48) 25 (18-39) 25 (14-48)
BMI, body mass index; dcSSc, diffuse cutaneous systemic sclerosis; lcSSc, limited cutaneous systemic sclerosis; MRSS, modified Rodnan skin score; N/A, not
applicable; SSc, systemic sclerosis.
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To examine changes in adiponectin levels over time,
serial serum samples that were from the same patients
and that were separated by more than 10 months were
examined in 27 patients. Eighteen received mycopheno-
late mofetil alone or in combination with methotrexate,
and seven received no specific disease-modifying therapy
([18] and Additional file 3). The results of the longitudi-
nal analysis indicated that changes in adiponectin levels
over time were inversely correlated with changes in skin
score during the same interval (r = -0.522, n = 27, P =
0.005) (Figure 2). There were no apparent differences in
changes in skin score or adiponectin levels associated
with specific treatments.
The adiponectin gene contains a conserved peroxisome
proliferator responsive element (PPRE) that is targeted
by activated PPAR-g, resulting in ligand-dependent
transcription [19]. To examine adiponectin regulation
in mesenchymal cells, growth-arrested confluent nor-
mal human preadipocytes or dermal fibroblasts were
incubated with the PPAR-g ligand pioglitazone for 48
hours. The results of real-time qPCR analysis indicated
increases of greater than threefold and greater than
ninefold in adiponectin mRNA levels of pioglitazone-
treated fibroblasts and preadipocytes, respectively (Fig-
ure 3a). Reduced levels of circulating adiponectin in
patients with early-stage dcSSc suggested attenuated
PPAR-g signaling during active fibrogenesis. To
explore this possibility, we examined adiponectin
mRNA expression in lesional SSc skin biopsies. For
this purpose, a published genome-wide expression pro-
filing dataset comprising biopsies of the lesional (clini-
cally affected) skin from 15 patients with early dcSSc
and six patients with lcSSc was queried [16]. A signifi-
cant correlation between adiponectin mRNA expres-
sion in the skin and MRSS was observed in the
individual biopsies (r = -0.44, n = 21, P = 0.044) (Fig-
ure 3b).
Taken together, the present results provide support
for the involvement of PPAR-g in modulation of skin
fibrogenesis in SSc and suggest that reduced adiponectin
levels might reflect reduced PPAR-g activity associated
with active or progressive skin fibrosis. Defective PPAR-
g activity in SSc contributes to unopposed fibroblast
activation and is implicated in pathogenesis [14]. Adipo-
nectin production is tightly regulated by PPAR-g, and its
levels in the serum represent a robust biomarker of
PPAR-g activity [15]. We found significantly lower
serum adiponectin levels in patients with dcSSc than in
those with lcSSc, and levels were lowest in the early
stage of disease, when fibrogenesis is presumed to be
the most active. A gradual rise in the levels of adiponec-
tin over time might parallel spontaneous or treatment-
associated skin regression and may signal attenuation of
fibrogenesis. The present studies did not compare adi-
ponectin levels in SSc with those with other autoimune
diseases. However, studies have shown that rheumatoid
arthritis, systemic lupus erythematosus, and other
immune and inflammatory disorders are generally asso-
ciated with elevated serum adiponectin [20-24]. Thus, it
Figure 1 Serum adiponectin levels in systemic sclerosis (SSc). Sera from 129 patients with limited (lcSSc) or diffuse (dcSSc) cutaneous SSc
and 86 controls were analyzed by multiplex assays. (a) Horizontal bars indicate median values in each group. (b) Correlation between
adiponectin levels and modified Rodnan skin score (MRSS) in all patients with SSc (left panel) and patients with Scl-70-positive SSc (right panel).
The solid line represents the linear regression line. (c) Adiponectin levels in patients with SSc according to disease duration (defined as duration
from first non-Raynaud manifestation). Horizontal bars indicate median values.
Figure 2 Changes in adiponectin levels over time . Serum
adiponectin levels were determined in 27 patients with diffuse
cutaneous systemic sclerosis at two time points separated by more
than 10 months. Changes in adiponectin levels are correlated with
contemporaneous changes of modified Rodnan skin score (MRSS).
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is noteworthy that, in contrast, SSc is not associated
with elevated adiponection, despite the chronic inflam-
mation that is thought to be a hallmark of this disease
[25].
The levels of adiponectin in the circulation reflect
PPAR-g signaling activity in mesenchymal cells [15].
Thus, reduced adiponectin levels and adiponectin gene
expression in lesional tissue in SSc indicate reduced adi-
ponectin production that results from the impaired
PPAR-g activity. Adiponectin directly suppresses fibro-
blast migration and myofibroblast differentiation and
blocks TGF-b-induced fibrotic responses, including col-
lagen synthesis [26]. Moreover, adiponectin-null mice
show exaggerated fibrogenesis in the heart, liver, and
kidneys, suggesting a potential anti-fibrotic role [27].
Whether adiponectin is simply a marker for PPAR-g sig-
naling or, in fact, mediates its anti-fibrotic activities is
currently unknown.
Conclusions
In summary, this cross-sectional analysis indicates that
the levels of the PPAR-g-regulated adiponectin are
reduced in early-stage dcSSc and are inversely correlated
with the skin score. Moreover, rising levels of adiponec-
tin over time correlate with improvement in skin score.
Reduced adiponectin reflecting impaired PPAR-g activity
might signify unopposed fibroblast activation and serve
as a biomarker for ongoing fibrogenesis. Two recent stu-
dies with fewer patients reported reduced adiponectin
levels in Japanese patients with SSc [20,28]. These find-
ings are consistent with our present results with a sig-
nificantly larger patient cohort of a different ethnic
background. Taken together, the results provide a com-
pelling case for a role of PPAR-g activity in skin fibrosis
in SSc and support the prospective evaluation of adipo-
nectin as a biomarker of fibrogenic activity.
Additional material
Additional file 1: Patient adiponectin levels according to clinical
and laboratory features. Adiponectin levels evaluated statistically in
different clinical and laboratory features. Significance was tested by Mann
Whitney (MW) test or Kruskal Wallis (KW) test. NS = not significant.
Pulmonary hypertension defined as estimated pulmonary artery systolic
pressure > 40 mmHg (Echo/Doppler), or mean pulmonary artery pressure
by right heart catheterization > 25 mmHg.
Additional file 2: Median levels of clinical/laboratory scores in
patients within different adiponectin quartiles and their correlation
coefficients. Correlation coefficients were determined using Spearman
rank correlation test. PA = mean pulmonary artery pressure based on
right heart catheterization. BNP = brain natriuretic peptide Interquartile
ranges are in parentheses. NS = not significant.
Additional file 3: Levels of adiponectin and MRSS in the
longitudinal study. Levels of adiponectin at 2 time points (visit 1:
MRSS1, adiponectin 1; visit 2: MRSS 2, adiponectin 2) with an indication
of time laps in between the two visits. MRSS = modified Rodnan skin
score.
Abbreviations
BMI: body mass index; dcSSc: diffuse cutaneous systemic sclerosis; DlCO:
carbon monoxide diffusion capacity; FVC: forced vital capacity; IQR:
interquartile range; lcSSc: limited cutaneous systemic sclerosis; MRSS:
modified Rodnan skin score; PH: pulmonary hypertension; PPAR-γ:
peroxisome proliferator-activated receptor gamma; qPCR: quantitative
polymerase chain reaction; SSc: systemic sclerosis; TGF-β: transforming
growth factor-beta.
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